Evolus, Inc. (0K16.L)

USD 11.39

(0.03%)

Long Term Debt Summary of Evolus, Inc.

  • Evolus, Inc.'s latest annual long term debt in 2023 was 120.35 Million USD , up 67.45% from previous year.
  • Evolus, Inc.'s latest quarterly long term debt in 2024 Q2 was 120.91 Million USD , up 0.23% from previous quarter.
  • Evolus, Inc. reported annual long term debt of 71.87 Million USD in 2022, down -2.18% from previous year.
  • Evolus, Inc. reported annual long term debt of 73.47 Million USD in 2021, up 68.32% from previous year.
  • Evolus, Inc. reported quarterly long term debt of 120.91 Million USD for 2024 Q2, up 0.23% from previous quarter.
  • Evolus, Inc. reported quarterly long term debt of 95.09 Million USD for 2023 Q3, down -0.4% from previous quarter.

Annual Long Term Debt Chart of Evolus, Inc. (2023 - 2015)

Historical Annual Long Term Debt of Evolus, Inc. (2023 - 2015)

Year Long Term Debt Long Term Debt Growth
2023 120.35 Million USD 67.45%
2022 71.87 Million USD -2.18%
2021 73.47 Million USD 68.32%
2020 43.65 Million USD -54.22%
2019 95.34 Million USD 464.04%
2018 16.9 Million USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%

Peer Long Term Debt Comparison of Evolus, Inc.

Name Long Term Debt Long Term Debt Difference
Editas Medicine, Inc. 24.37 Million USD -393.841%
Dynavax Technologies Corporation 252.41 Million USD 52.318%
Supernus Pharmaceuticals, Inc. 33.19 Million USD -262.571%
Perrigo Company plc 3.63 Billion USD 96.687%
Illumina, Inc. 1.48 Billion USD 91.917%
Thermo Fisher Scientific Inc. 31.3 Billion USD 99.616%
Iovance Biotherapeutics, Inc. 1 Million USD -11935.9%
Walgreens Boots Alliance, Inc. 8.04 Billion USD 98.504%
IQVIA Holdings Inc. 12.95 Billion USD 99.071%
Heron Therapeutics, Inc. 173.75 Million USD 30.73%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 95.547%
Unity Biotechnology, Inc. 23.53 Million USD -411.317%
Waters Corporation 2.3 Billion USD 94.78%
Biogen Inc. 7.18 Billion USD 98.326%
Sangamo Therapeutics, Inc. 33.51 Million USD -259.12%
Adicet Bio, Inc. 17.7 Million USD -579.879%
Cara Therapeutics, Inc. 37.07 Million USD -224.602%
bluebird bio, Inc. 224.41 Million USD 46.369%
Esperion Therapeutics, Inc. 501.54 Million USD 76.002%
FibroGen, Inc. 89.69 Million USD -34.184%
Agilent Technologies, Inc. 2.73 Billion USD 95.599%
Corbus Pharmaceuticals Holdings, Inc. 3.23 Million USD -3616.354%
Homology Medicines, Inc. 43.17 Million USD -178.764%
Geron Corporation 35.05 Million USD -243.382%
Alnylam Pharmaceuticals, Inc. 2.34 Billion USD 94.863%
Amicus Therapeutics, Inc. 387.85 Million USD 68.968%
Myriad Genetics, Inc. 130.9 Million USD 8.053%
Viking Therapeutics, Inc. 936 Thousand USD -12758.868%
Intellia Therapeutics, Inc. 96.74 Million USD -24.406%
Zoetis Inc. 6.56 Billion USD 98.166%
Abeona Therapeutics Inc. 4.4 Million USD -2634.189%
Mettler-Toledo International Inc. 1.97 Billion USD 93.908%
BioMarin Pharmaceutical Inc. 593.09 Million USD 79.707%
Vertex Pharmaceuticals Incorporated 724.7 Million USD 83.392%
Kala Pharmaceuticals, Inc. 34.19 Million USD -252.03%
Ionis Pharmaceuticals, Inc. 1.4 Billion USD 91.405%
Atara Biotherapeutics, Inc. 45.69 Million USD -163.408%
Verastem, Inc. 40.08 Million USD -200.252%
Nektar Therapeutics 112.62 Million USD -6.867%
Axsome Therapeutics, Inc. 178.07 Million USD 32.409%
Aclaris Therapeutics, Inc. 3.07 Million USD -3815.387%
Sarepta Therapeutics, Inc. 1.13 Billion USD 89.372%
OPKO Health, Inc. 222.03 Million USD 45.793%
Exelixis, Inc. 189.94 Million USD 36.634%
Neurocrine Biosciences, Inc. 258.3 Million USD 53.403%
Corcept Therapeutics Incorporated - USD -Infinity%
Anavex Life Sciences Corp. - USD -Infinity%
uniQure N.V. 130.06 Million USD 7.462%
Imunon, Inc. 1.13 Million USD -10464.359%
Blueprint Medicines Corporation 610.96 Million USD 80.3%
Insmed Incorporated 1.19 Billion USD 89.914%
Halozyme Therapeutics, Inc. 1.49 Billion USD 91.972%
Agios Pharmaceuticals, Inc. 56.98 Million USD -111.201%
TG Therapeutics, Inc. 100.11 Million USD -20.217%
Incyte Corporation 29.16 Million USD -312.725%
Emergent BioSolutions Inc. 446.5 Million USD 73.044%